VitaCholine®

Search documents
 Balchem(BCPC) - 2025 Q3 - Earnings Call Presentation
 2025-10-21 15:00
2 • During the course of this presentation, management may make forward-looking statements regarding financial performance and future events. • These forward-looking statements generally are identified by the words "believe," "project," "expect," "anticipate," "estimate," "forecast," "outlook," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," or the negative thereof or variations thereon or similar expressions generall ...
 Balchem(BCPC) - 2025 Q2 - Earnings Call Presentation
 2025-07-31 15:00
 Financial Performance - Q2 2025 - Sales increased by 9.1% to $255.5 million in Q2 2025, compared to $234.1 million in Q2 2024[54] - Adjusted EBITDA increased by 11.2% to $69.2 million in Q2 2025[56] - Adjusted Net Earnings increased by 16.8% to $41.6 million in Q2 2025, compared to $35.6 million in Q2 2024[58] - Adjusted EPS increased by 16.5% to $1.27 per share in Q2 2025, compared to $1.09 per share in Q2 2024[59, 60]   Financial Performance - YTD 2025 - Sales increased by 6.8% to $506.0 million YTD 2025, compared to $473.7 million YTD 2024[63] - Adjusted EBITDA increased by 10.1% to $135.5 million YTD 2025[65] - Adjusted Net Earnings increased by 18.0% to $81.6 million YTD 2025, compared to $69.2 million YTD 2024[67] - Adjusted EPS increased by 17.5% to $2.49 per share YTD 2025, compared to $2.12 per share YTD 2024[69]   Overall Company Financials - 2024 Sales were $954 million[9] - 2024 Adjusted EBITDA was $250 million with a margin of 26.3%[11]
 Balchem(BCPC) - 2025 Q1 - Earnings Call Presentation
 2025-04-24 22:53
 Financial Performance - Balchem's 2024 sales reached $954 million[9] - The company's 2024 adjusted EBITDA was $250 million, with a margin of 26.3%[12] - In Q1 2025, sales grew by 4.5% to $250.5 million from $239.7 million in Q1 2024[57] - Adjusted EBITDA for Q1 2025 increased by 8.9% to $66.3 million compared to $60.9 million in Q1 2024[59] - Adjusted net earnings for Q1 2025 rose by 19.2% to $40.0 million from $33.6 million in Q1 2024[61] - Adjusted EPS for Q1 2025 grew by 18.4% to $1.22 per share from $1.03 per share in Q1 2024[63]   Business Segments - Human Nutrition & Health accounted for 63% of Balchem's 2024 revenue[15] - Animal Nutrition & Health contributed 23% to the company's 2024 revenue[15] - Specialty Products represented 14% of Balchem's 2024 revenue[15]   Sustainability - Balchem reached 1.2 billion people in 2024 through its products[86] - The company has reduced its Scope 1 and 2 GHG emissions by 32%, surpassing its 2030 goal[91] - Balchem has reduced its water withdrawal by 15% from the baseline and is on track to meet its 2030 goal[93]
